Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-26 @ 12:26 AM
Study NCT ID:
NCT00145860
Status:
TERMINATED
Last Update Posted:
2013-09-05
First Post:
2005-09-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Do Patients With Colorectal Cancer Understand That Their Family is at Risk?
Sponsor:
University of Chicago
Organization:
Study Overview
Official Title:
Do Patients With Colorectal Cancer Understand That Their Family is at Increased Risk?
Status:
TERMINATED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess whether patients with colorectal cancer understand that their first-degree relatives are at increased risk of getting the cancer themselves and therefore should be screened early. Among patients who do understand the risks to their family, we plan to determine who they identify as the source of their information and whether they have acted upon this information and advised family members to be screened. We hypothesize that many patients with colorectal cancer do not have a correct understanding of the risks to their first-degree relatives and the recommendations that they be screened early.
If this hypothesis is shown to be true, it can be used to direct improved and more diligent patient education. This, in turn, will hopefully increase the low screening rates among first-degree relatives, and, thereby, save lives in this high-risk population.
If this hypothesis is shown to be true, it can be used to direct improved and more diligent patient education. This, in turn, will hopefully increase the low screening rates among first-degree relatives, and, thereby, save lives in this high-risk population.
Detailed Description:
1. The primary physician of patients with colorectal cancer will be contacted and asked permission to contact their patient to discuss his or her understanding of familial risk before patient is contacted.
2. A letter will be sent to all patients prior to being contacted, notifying them that all identifying information will be kept confidential and they may decline to participate at any time.
3. Patients will be called and asked a series of questions about their understanding of familial risk of colon cancer, the need for early screening and where they learned what they know. If the patient has lacking knowledge they will be educated.
4. Each patient will be sent informational brochures about colon cancer after the phone survey.
5. Six months later, the patients will be contacted again and asked a series of questions about their understanding of familial risk of colon cancer and the need for early screening to access how much impact the informational brochures had on their knowledge of cancer risk. Patients will be asked one additional demographic question about the highest level of education that they have completed.
2. A letter will be sent to all patients prior to being contacted, notifying them that all identifying information will be kept confidential and they may decline to participate at any time.
3. Patients will be called and asked a series of questions about their understanding of familial risk of colon cancer, the need for early screening and where they learned what they know. If the patient has lacking knowledge they will be educated.
4. Each patient will be sent informational brochures about colon cancer after the phone survey.
5. Six months later, the patients will be contacted again and asked a series of questions about their understanding of familial risk of colon cancer and the need for early screening to access how much impact the informational brochures had on their knowledge of cancer risk. Patients will be asked one additional demographic question about the highest level of education that they have completed.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: